Good morning,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Quick update from me.
If you missed my initiation note on Emyria (ASX: EMD), you can read the full article here: My Second Armchair Pick: Emyria (ASX: EMD)
There was also some relevant coverage on the recent Trump Executive Order that I thought was worth highlighting:
5-minute breakdown from the senior editor at Pshcadelic Alpha (Watch, Twitter)
Detailed report on the announcement (Psychadelic Alpha)
Trump conference announcing the executive order (YouTube)
The key takeaway from me is that there are three applications imminent for the FDA approval of psychedelic therapies, and the government will be issuing Priority Review Vouchers within the next week.
This is a big shift from where the administration was in October, rejecting Compass Therapeutics applic’ application for a PRV.
(Compass is the most advanced of the big companies in the US running clinical trials for psychedelic therapies)
So this is just the starting gun for the psychedelic-assisted therapy industry in the US.
With it looking more and more likely that the US will have an approved psychedelic therapy in the next 12-months…
The ONLY organisation to actually scale the delivery service model is EMD.
A true star aligns moment for the company.
I’m looking forward to following Emyria for the next 12 months and beyond.
Let’s dive in…
The Pulse Check
Tetratherix (ASX: TTX) partner Superpower Health just launched Peptides by Superpower. (LinkedIn)
🪑 TTX signed an agreement with Superpower Health last month to deliver peptide nasal spray technology, which could be a central differentiator for Superpower’s peptide products.
The more nasal spray peptides that Superpower Health sells, the more product that it needs to purchase from TTX. Presenting an immediate and near-term revenue opportunity.
TTX is my first Armchair Analyst Pick.
Monash IVF (ASX: MVF) rejects a $0.90 acquisition proposal from Genesis Capital and Soul Patts. (MVF)
🪑 The saga continues.
4DMedical (ASX: 4DX) secures a contract with GSK for lung imaging analytics. (4DX)
🪑 An interesting data play from 4DX.
GSK is a top name in the pharmaceutical industry, and while the deal is not material in terms of revenue, it does validate 4DX’s technology.
Nexalis Therapeutics (ASX: NX1) announces the first patient screened in the Phase 2 trial of IRX-211 (inhaled cannabis therapy) for Breakthrough Cancer Pain. (NX1)
Emyria (ASX: EMD) launches the Empax Global Partnership Program to offer high-margin services for global drug sponsors, leveraging its unique clinical delivery infrastructure. (EMD)
🪑 This program adds another string to EMD’s bow, leveraging its network of trained therapists and purpose-built clinics to run trials of US-based companies.
Importantly, it opens additional treatment pathways for patients who may not have insurance coverage (through either Medibank or the Department of Veterans Affairs), thereby increasing demand for EMD’s services.
EMD is my second Armchair Analyst pick.
The Report Card
Orthocell (ASX: OCC) reports $3.2M quarterly revenue, driven by U.S. Remplir sales ($300k), with U.S. market penetration showing strong early growth. (OCC)
🪑 Just an okay quarterly result from OCC. I’m hoping that by next quarter, the revenues (particularly outside the US) will start to reflect the company’s momentum.
Medical device sales take time - so shareholders should be patient here.
Cash Injection
Patrys (ASX: PAB) raises $3.2M via a share placement at $0.024/share to fund Phase 1A clinical trials for its injectable reformulated product for delirium. (PAB)
🪑 Nice raise, small discount.
See you all tomorrow,
The Armchair Analyst
